fda glp-1 warning 2025 november Pharmacovigilance analysis of neurological adverse events associated with receptor agonists based on the Adverse Event Reporting System Q1 2026 in Review: Milsaperidone,

& Wachtveitl, J

Outside China, I can only find one public company with FDA-inspected, ton-scale capacity ready to go live in H2 2025: Bachem Holding AG (SWX: BANB)

248 (3 pt 1): G3139 Rebouche C, Mack D, Edmonson P

References Lin'kova, N

As of 2026, retatrutide has not been approved by the MHRA, FDA, EMA, or any other regulatory authority for human or veterinary use

2.4.4 The association between microplastics and central nervous system neoplasms Toxicological testing and metabolic profiling results demonstrate that nano/micron polystyrene materials (n/mPS) exert significant toxic effects on SH-SY5Y human neuroblastoma cells, with enhanced toxicity under oxidative conditions ultimately leading to cytotoxicity and metabolic disturbances (59), revealing microplastics intervention in tumor cells